LearnGlossaryMarketStocksSuperinvestorsSign in

SCYX

SCYNEXIS, Inc.

Healthcare · $30M market cap

Verdict

We can't put a fair value on SCYX right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-27.7% a year✗
Sales growth-2.7% a year✗
Free cash flow growth—?
Return on invested capital-3.8%✗

Follow SCYX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 9, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

Subramanian Sanjay

Chief Financial Officer · 2026-09-09

Award

$491K

About SCYNEXIS, Inc.

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J…

Medical - Pharmaceuticals

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works